NCT00673556View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

PHASE3CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Chronic Plaque Psoriasis
Interventions
DRUG

alefacept

Intramuscular (IM)

DRUG

placebo

Intramuscular (IM)

Trial Locations (34)

1070

Brussels

1090

Vienna

2650

Edegem

4020

Liège

20246

Hamburg

23507

Norfolk

27157

Winston-Salem

30449

Hanover

37072

Goodlettsville

37075

Göttingen

40225

Düsseldorf

44791

Bochum

45147

Essen

48149

Münster

60596

Frankfurt

66421

Homburg-Saar

68135

Mannheim

68144

Omaha

75246

Dallas

84132

Salt Lake City

90404

Santa Monica

92697

Irvine

98104

Seattle

08903

New Brunswick

T5J 3S9

Edmonton

A1B 4S8

St. John's

B3H 1Z4

Halifax

L4K 5V2

Concord

L8N 1V6

Hamilton

N6K 1L6

London

N8W 5L7

Windsor

H2K 4L5

Montreal

G1V 4X7

Sainte-Foy

01307

Dresden

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00673556 - A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate | Biotech Hunter | Biotech Hunter